Rucaparib for Non-Small Cell Lung Cancer

Recruiting in Palo Alto (17 mi)

+949 other locations

Overseen byJonathan W Riess

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: SWOG Cancer Research Network

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligibility Criteria

This trial is for adults with stage IV or recurrent non-small cell lung cancer that have high genomic loss of heterozygosity (LOH) or harmful BRCA1/2 mutations. Participants must be able to take oral medications, not have certain liver conditions, infections, or recent major surgeries. They should not have had prior treatment with PARP inhibitors and must agree to use effective contraception if of reproductive potential.

Inclusion Criteria

I am not planning to receive any cancer treatments other than this study's treatment.

My liver function tests are within the required range.

I do not have severe heart disease or recent serious heart issues.

See 24 more

Exclusion Criteria

Not applicable.

Treatment Details

Interventions

Rucaparib (PARP Inhibitor)

Trial OverviewThe trial is testing the effectiveness of Rucaparib, a drug designed to block enzymes needed for tumor growth in patients with specific genetic profiles related to lung cancer. It's a phase II study which means it focuses on the drug's efficacy and side effects.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Treatment (rucaparib)Experimental Treatment1 Intervention

Patients receive rucaparib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.